{"nctId":"NCT00146770","briefTitle":"Phase 3 Extension Study of the Safety and Efficacy of AldurazymeÂ® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients","startDateStruct":{"date":"2001-05"},"conditions":["Mucopolysaccharidosis I","Hurler's Syndrome","Hurler-Scheie Syndrome","Scheie Syndrome"],"count":45,"armGroups":[{"label":"Placebo/Aldurazyme","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Aldurazyme","Biological: placebo"]},{"label":"Aldurazyme/Aldurazyme","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Aldurazyme"]}],"interventions":[{"name":"Aldurazyme","otherNames":[]},{"name":"Aldurazyme","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient or patient's legal guardian must provide written informed consent prior to any protocol-related procedures being performed.\n* The patient must have successfully completed Study ALID-003-99 (who received 21 of 26 consecutive weekly infusions).\n* The patient has not experienced any safety issues that would contraindicate participation in the Extension study.\n* A female patient of childbearing potential must have a negative pregnancy test at entry\n\nExclusion Criteria:\n\n* The patient is pregnant or lactating.\n* The patient has received an investigational drug within 30 days prior to the study enrollment.\n* The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 182 in Percent Predicted Forced Vital Capacity (FVC)","description":"Percent Predicted Forced Vital Capacity: the maximal exhaled breath volume following a maximal inhaled breath. Overall change from Baseline to Week 182 in percent predicted FVC = (observed value)/(predicted value) \\* 100%). A higher value indicates a greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":"13.15"},{"groupId":"OG001","value":"48.4","spread":"14.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":"13.69"},{"groupId":"OG001","value":"47.2","spread":"15.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"9.07"},{"groupId":"OG001","value":"-1.2","spread":"6.52"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 182 in Six Minute Walk Test (6MWT)","description":"Six Minute Walk Test: Distance walked (measured in Meters) in 6 minutes. A longer distance indicates a greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348.3","spread":"128.81"},{"groupId":"OG001","value":"319.0","spread":"131.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"367.7","spread":"151.25"},{"groupId":"OG001","value":"358.3","spread":"126.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"107.36"},{"groupId":"OG001","value":"39.2","spread":"85.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 182 in Apnea/Hypopnea Index (AHI)","description":"Apnea/Hypopnea Index (AHI): Number of absent (apnea) and shallow (hypopnea) breaths per hour of sleep. A greater decrease in events indicates a greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":"12.90"},{"groupId":"OG001","value":"18.0","spread":"15.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"14.60"},{"groupId":"OG001","value":"14.0","spread":"19.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"13.86"},{"groupId":"OG001","value":"-4.0","spread":"12.91"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 182 in Liver Volume","description":"Liver Organ Volume: Volume of liver measured by Magnetic Resonance Imaging (MRI). Greater decrease in volume indicates a greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1351.6","spread":"323.71"},{"groupId":"OG001","value":"1228.5","spread":"279.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1079.9","spread":"256.99"},{"groupId":"OG001","value":"1001.4","spread":"157.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.6","spread":"20.21"},{"groupId":"OG001","value":"-16.1","spread":"14.76"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 182 in Child Health Assessment Questionnaire/Health Assessment Questionnaire (CHAQ/HAQ) Disability Index Score","description":"CHAQ/HAQ = Patient questionnaire that measures the degree of disability on a scale of 0 (no disability) to 3 (maximal disability). A lower score indicates a greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"0.740"},{"groupId":"OG001","value":"1.99","spread":"0.496"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"0.768"},{"groupId":"OG001","value":"1.56","spread":"0.758"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.688"},{"groupId":"OG001","value":"-0.43","spread":"0.574"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 182 in Active Joint Range of Motion (ROM)","description":"Active Joint Range of Motion (ROM): Shoulder Flexion Ability to maximally raise one's arm overhead without assistance. Shoulder range of motion (mean of left and right arms) measured in degrees (0-180) by goniometry. Greater degree of flexion indicates greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":"32.66"},{"groupId":"OG001","value":"96.1","spread":"30.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.5","spread":"23.34"},{"groupId":"OG001","value":"109.2","spread":"22.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"21.59"},{"groupId":"OG001","value":"13.1","spread":"20.66"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to Week 182 in Urinary GAG Level","description":"Urinary Glycosaminoglycan (GAG) Levels: \\>\\> Concentration of GAG relative to creatinine in urine. A greater decrease in GAG level indicates a greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250.2","spread":"105.09"},{"groupId":"OG001","value":"190.2","spread":"59.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":"30.88"},{"groupId":"OG001","value":"59.8","spread":"34.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.0","spread":"10.09"},{"groupId":"OG001","value":"-66.3","spread":"21.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":23},"commonTop":["Headache","Nasopharyngitis","Pyrexia","Cough","Pain in extremity"]}}}